Pediatrics:教育干预能否增加HPV疫苗接种率?

2019-02-13 吴星 环球医学

2019年1月,发表于《Pediatrics》上的一项研究,表明了基于诊所的教育干预有望增加人乳头瘤病毒(HPV)疫苗的接种率。

2019年1月,发表于《Pediatrics》上的一项研究,表明了基于诊所的教育干预有望增加人乳头瘤病毒(HPV)疫苗的接种率。

背景:HPV感染会导致严重的健康疾病,它也是最常见的性传播感染疾病。尽管有效的疫苗已经面世,但疫苗的接种率仍然不够理想。

方法:通过一项整群随机对照试验评价了在儿童诊所中对符合HPV疫苗接种标准的青少年(11岁~17岁)的父母进行教育干预的效果。具体干预措施为父母在检查室观看一段介绍HPV疫苗风险及获益的科普视频。主要结局为2周后HPV疫苗接种状态的变化。使用广义估计方程对主要结局进行意向性分析,以调整诊所间的整群效应。

结果:在为期7个月的试验中共纳入1596例符合标准的青少年。三分之一的青少年在有教育干预的诊所就诊。在干预诊所就诊的青少年比在对照诊所就诊的青少年年轻(11~12岁的比例:72.4% vs 49.8%;P<0.001),在种族和性别上没有差异。干预诊所青少年疫苗接种状态发生变化的比例(64.8%)高于控制诊所的青少年(50.1%;比值比,1.82;95%置信区间,1.47~2.25;P<0.001)。家长观看视频后,青少年的HPV疫苗接种率高出3倍(78.0%;比值比,3.07;95% 置信区间,1.47~6.42;P=0.003)。

结论:在诊所进行教育干预有望改善疫苗接种行为。

原始出处:

Dixon BE, Zimet GD, Xiao S, et.al. An Educational Intervention to Improve HPV Vaccination: A Cluster Randomized Trial. Pediatrics. 2019 Jan;143(1). pii: e20181457. doi: 10.1542/peds.2018-1457. Epub 2018 Dec 10.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1946278, encodeId=e18519462e840, content=<a href='/topic/show?id=0e1c9083cc' target=_blank style='color:#2F92EE;'>#HPV疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9083, encryptionId=0e1c9083cc, topicName=HPV疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Sat Oct 26 13:38:00 CST 2019, time=2019-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638988, encodeId=78f81638988a9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Jul 18 07:38:00 CST 2019, time=2019-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727888, encodeId=89281e27888f9, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Sep 07 03:38:00 CST 2019, time=2019-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078658, encodeId=bd5520e8658db, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Sat Aug 03 03:38:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958543, encodeId=60371958543d0, content=<a href='/topic/show?id=766713993a1' target=_blank style='color:#2F92EE;'>#Pediatric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13993, encryptionId=766713993a1, topicName=Pediatric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Jul 21 20:38:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257863, encodeId=7381125e86369, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Fri Feb 15 04:38:00 CST 2019, time=2019-02-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1946278, encodeId=e18519462e840, content=<a href='/topic/show?id=0e1c9083cc' target=_blank style='color:#2F92EE;'>#HPV疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9083, encryptionId=0e1c9083cc, topicName=HPV疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Sat Oct 26 13:38:00 CST 2019, time=2019-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638988, encodeId=78f81638988a9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Jul 18 07:38:00 CST 2019, time=2019-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727888, encodeId=89281e27888f9, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Sep 07 03:38:00 CST 2019, time=2019-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078658, encodeId=bd5520e8658db, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Sat Aug 03 03:38:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958543, encodeId=60371958543d0, content=<a href='/topic/show?id=766713993a1' target=_blank style='color:#2F92EE;'>#Pediatric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13993, encryptionId=766713993a1, topicName=Pediatric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Jul 21 20:38:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257863, encodeId=7381125e86369, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Fri Feb 15 04:38:00 CST 2019, time=2019-02-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1946278, encodeId=e18519462e840, content=<a href='/topic/show?id=0e1c9083cc' target=_blank style='color:#2F92EE;'>#HPV疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9083, encryptionId=0e1c9083cc, topicName=HPV疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Sat Oct 26 13:38:00 CST 2019, time=2019-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638988, encodeId=78f81638988a9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Jul 18 07:38:00 CST 2019, time=2019-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727888, encodeId=89281e27888f9, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Sep 07 03:38:00 CST 2019, time=2019-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078658, encodeId=bd5520e8658db, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Sat Aug 03 03:38:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958543, encodeId=60371958543d0, content=<a href='/topic/show?id=766713993a1' target=_blank style='color:#2F92EE;'>#Pediatric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13993, encryptionId=766713993a1, topicName=Pediatric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Jul 21 20:38:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257863, encodeId=7381125e86369, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Fri Feb 15 04:38:00 CST 2019, time=2019-02-15, status=1, ipAttribution=)]
    2019-09-07 feather89
  4. [GetPortalCommentsPageByObjectIdResponse(id=1946278, encodeId=e18519462e840, content=<a href='/topic/show?id=0e1c9083cc' target=_blank style='color:#2F92EE;'>#HPV疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9083, encryptionId=0e1c9083cc, topicName=HPV疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Sat Oct 26 13:38:00 CST 2019, time=2019-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638988, encodeId=78f81638988a9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Jul 18 07:38:00 CST 2019, time=2019-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727888, encodeId=89281e27888f9, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Sep 07 03:38:00 CST 2019, time=2019-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078658, encodeId=bd5520e8658db, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Sat Aug 03 03:38:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958543, encodeId=60371958543d0, content=<a href='/topic/show?id=766713993a1' target=_blank style='color:#2F92EE;'>#Pediatric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13993, encryptionId=766713993a1, topicName=Pediatric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Jul 21 20:38:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257863, encodeId=7381125e86369, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Fri Feb 15 04:38:00 CST 2019, time=2019-02-15, status=1, ipAttribution=)]
    2019-08-03 gous
  5. [GetPortalCommentsPageByObjectIdResponse(id=1946278, encodeId=e18519462e840, content=<a href='/topic/show?id=0e1c9083cc' target=_blank style='color:#2F92EE;'>#HPV疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9083, encryptionId=0e1c9083cc, topicName=HPV疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Sat Oct 26 13:38:00 CST 2019, time=2019-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638988, encodeId=78f81638988a9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Jul 18 07:38:00 CST 2019, time=2019-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727888, encodeId=89281e27888f9, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Sep 07 03:38:00 CST 2019, time=2019-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078658, encodeId=bd5520e8658db, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Sat Aug 03 03:38:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958543, encodeId=60371958543d0, content=<a href='/topic/show?id=766713993a1' target=_blank style='color:#2F92EE;'>#Pediatric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13993, encryptionId=766713993a1, topicName=Pediatric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Jul 21 20:38:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257863, encodeId=7381125e86369, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Fri Feb 15 04:38:00 CST 2019, time=2019-02-15, status=1, ipAttribution=)]
    2019-07-21 hbwxf
  6. [GetPortalCommentsPageByObjectIdResponse(id=1946278, encodeId=e18519462e840, content=<a href='/topic/show?id=0e1c9083cc' target=_blank style='color:#2F92EE;'>#HPV疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9083, encryptionId=0e1c9083cc, topicName=HPV疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Sat Oct 26 13:38:00 CST 2019, time=2019-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638988, encodeId=78f81638988a9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Jul 18 07:38:00 CST 2019, time=2019-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727888, encodeId=89281e27888f9, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Sep 07 03:38:00 CST 2019, time=2019-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078658, encodeId=bd5520e8658db, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Sat Aug 03 03:38:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958543, encodeId=60371958543d0, content=<a href='/topic/show?id=766713993a1' target=_blank style='color:#2F92EE;'>#Pediatric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13993, encryptionId=766713993a1, topicName=Pediatric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Jul 21 20:38:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257863, encodeId=7381125e86369, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Fri Feb 15 04:38:00 CST 2019, time=2019-02-15, status=1, ipAttribution=)]

相关资讯

临床大发现,HPV感染有救了!

根据世界卫生组织的数据,2012年世界范围内HPV感染导致约266,000例宫颈癌死亡。与全球欠发达地区相比,通过子宫颈抹片检查或HPV DNA检测进行的常规筛查降低了发达国家的死亡率。尽管如此,估计每年有12,200名美国女性被诊断患有宫颈癌。

CLIN CANCER RES:靶向HPV16/18的免疫治疗在HPV相关头颈部肿瘤中可以诱导免疫反应

约20%的晚期头颈部鳞状细胞癌(HNSCCa)患者对PD-1抗体存在临床反应。病毒新抗原,例如HPV16 / 18的E6 / E7蛋白,是免疫治疗的潜在靶点,可与PD-1抑制免疫激活互补。MEDI0457是一种靶向HPV16 / 18 E6 / E7的DNA免疫疗法。CLIN CANCER RES近期发表了一篇文章,报道了MEDI0457治疗HNSCCa患者的效果。

九价HPV“一苗难求”,深圳第二期摇号中签率1.21%

2018年第2期深圳市九价HPV疫苗摇号结果25日出炉,此次摇号共有119140位有效申请者,1441名申请者中签,中签率约为1.21%。深圳市疾控中心提示,中签者须在12月27日22:00前预约,接种时,要出示预约成功信息、身份证原件,如果现场无法核实身份,将不能接种。中签者如放弃预约,将被关“小黑屋”,3个月内不能参加摇号。此次,近12万人申请九价HPV疫苗摇号,参与热度较高。对此,深圳市疾控

BMJ:高危人乳头瘤病毒筛查、细胞学筛查与宫颈病变

研究认为,原发性高风险人乳头瘤病毒筛查可提高40%的2级以上宫颈上皮内瘤变和30%宫颈癌检查率,同时2项检查的敏感性极高,阴性人群3年内进展风险极低,建议可适当延长筛查间隔

九价HPV疫苗在北京遍地难寻,网上却有“黄牛”高价兜售

虽然九价HPV疫苗在北京遍地难寻,可是电商平台上却正在火热销售。对此有业内人士分析,这应该是九价HPV疫苗网上被黄牛了。他们的操作手法和号贩子类似:提前在社区接种门诊预约排队获取名额,然后再在网上翻倍加价,把接种资格转手卖给真正有接种需求的人群。深圳市11月26日即将开始推出摇号接种九价宫颈癌(HPV)疫苗,使得该疫苗“一针难求”的状况引发网络热议。北京青年报记者随后调查了北京十几家社区免疫

PNAS:新发现!抗癌药物或有助于治疗HPV感染

抗癌药物vorinostat、belinostat和panobinostat或可以被用于治疗由人乳头瘤病毒(HPV)引起的感染。